Danish pharmaceutical company Novo Nordisk has reported that its experimental obesity treatment, CagriSema, achieved an average weight loss of 25% among women with overweight or obesity in a recent late-stage clinical trial analysis. The findings point toward a potentially more potent therapeutic option in global markets where injectable weight-loss treatments have already gained significant traction.

The fixed-dose medication pairs semaglutide, the active ingredient found in Wegovy and Ozempic, with cagrilintide, a compound that mimics the natural appetite-regulating hormone amylin. Taken as a once-weekly injection, the combination targets two distinct biological pathways involved in controlling hunger and food consumption.

Data for this evaluation emerged from a post-hoc analysis of the phase 3 REDEFINE 1 trial, which involved more than 3,400 adults dealing with overweight or obesity. Among the 2,309 female participants evaluated, individuals taking CagriSema shed an average of 25% of their total body weight over a 68-week period, contrasted with a 3% reduction seen in the placebo group.

A separate sub-analysis looked at the treatment's performance across different transitional phases of menopause, a period when hormonal shifts frequently drive weight gain and stubborn abdominal fat accumulation. Researchers observed an average weight reduction of 26.7% in premenopausal women, 24.8% in perimenopausal individuals, and 23.1% among postmenopausal participants.

While these results indicate that significant weight reduction is attainable across various menopausal categories, company representatives have emphasized that the evaluations were exploratory and necessitate additional research. Furthermore, these metrics reflect trial efficacy standards assuming patients maintained continuous treatment, rather than serving as a guarantee of identical outcomes in everyday medical practice.

When evaluated alongside existing treatments, CagriSema utilizes a dual mechanism by activating the GLP-1 receptor via semaglutide while simultaneously engaging the amylin pathway through cagrilintide. In contrast, standard semaglutide monotherapy operates exclusively on the GLP-1 pathway, while alternative agents like tirzepatide target both GLP-1 and GIP receptors.

Across the broader REDEFINE 1 trial population, CagriSema delivered an average weight loss of 22.7% at 68 weeks, falling slightly short of the company's initial 25% goal. This compares against typical weight reductions of roughly 15% observed with standard semaglutide doses and approximately 20% achieved with high-dose tirzepatide in pivotal trials, though cross-trial comparisons do not definitively prove the superiority of any single medication.

In a separate head-to-head phase 3 evaluation, CagriSema produced a 23% weight reduction after 84 weeks but did not establish non-inferiority to the 15 mg dose of tirzepatide. CagriSema remains strictly an investigational asset and has not yet received regulatory approval or commercial availability anywhere in the world.